ALK EML4-ALK Method of providing the information for selecting the drugs for treating EML4-ALK positive non-small-cell lung cancer resistant to ALK inhibitors

摘要

The present invention provides a biomarker for providing information on drug selection for the treatment of EML4-ALK-positive non-small-cell lung cancer which has acquired resistance to ALK inhibitors. The present invention can provide a method, a composition, and a kit for detecting the expression levels of miR-34a and/or miR-449 to provide information on drug selection for the treatment of EML4-ALK-positive non-small-cell lung cancer which has acquired resistance to ALK inhibitors.